Which laboratory result best supports decompensated Congestive Heart Failure in a dyspneic patient?

Brain natriuretic peptide (BNP), or its precursor NT-proBNP, is the laboratory marker most closely associated with ventricular wall stress and volume overload, making it the best diagnostic and prognostic tool for decompensated congestive heart failure in a dyspneic patient. BNP is released by ventricular myocytes in response to increased wall tension and stretching, which occur when the failing heart is unable to manage preload. Elevated BNP levels strongly correlate with the presence and severity of heart failure and are used clinically to differentiate cardiac from pulmonary causes of dyspnea. Troponin I (option A) is an indicator of myocardial necrosis, most notably in acute myocardial infarction. While it may be mildly elevated in severe heart failure due to myocardial strain, it is not specific or sensitive enough to diagnose decompensated heart failure as the primary condition. D-dimer (option C) is elevated in thromboembolic events such as pulmonary embolism and deep vein thrombosis, not primarily in heart failure. C-reactive protein (option D) is a nonspecific marker of systemic inflammation and may be elevated in many conditions including infection, autoimmune disease, and cardiovascular disease, but it does not directly assess cardiac function or volume status. BNP remains the gold standard laboratory test for supporting a diagnosis of decompensated heart failure.